Laobaixing pushes buybacks, incentives, and new business bets
Buyback and dual incentive plan signal confidence Laobaixing launched a 40–80 million yuan share buyback plus restricted stock and employee ownership plans for over 340 people, with net profit targets of at least 75% growth in 2027 and 100% in 2028. This aligns management with shareholders and supports the stock price.
This is the biggest new event, directly boosting investor confidence and the share price.
Buyback already executed, returning cash to shareholders By September 30, 2026, Laobaixing had repurchased 3.24 million shares for 41.62 million yuan at 12.55–13.03 yuan per share. This shows the buyback is actually happening, which can support the share price by reducing shares outstanding.
It confirms the earlier buyback plan is being carried out, a concrete positive for the stock.
New pharmacy-plus venture and internet hospital expand business Laobaixing will invest 5.1 million yuan for 51% of a new company to explore a pharmacy-plus format, and it fully owns a new internet hospital in Chengdu. These small bets aim to create new growth beyond traditional drugstores.
These are new business initiatives that could drive future growth, a positive for the stock.
Interim profit steady but cash flow and margins weaken First-half 2026 revenue was 10.998 billion yuan and net profit 447 million yuan, but operating cash flow fell 13.66% and gross margin slipped. The profit is a positive, yet weaker cash and margins are a real counterweight for investors.
It gives the fundamental backdrop and a fair counterweight to the positive news.